Nasus Pharma Ltd NSRX
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $1.24B · Filed Mar 25, 2026
Nasus Pharma Ltd (NSRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 billion and a net loss of $5.9 million. Free cash flow was -$4.9 million. As of Dec 31, 2025 it held $1.2 million in cash and investments and $118,000 in total debt.
Revenue
$1.24B
Net income
$-5.86M
Operating cash flow
$-4.92M
Free cash flow
$-4.93M
EPS
$-0.72
Dividend per share
None
Shares outstanding
9.02M
Net cash
$1.12M
FY 2025
Operating margin
-0.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NSRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv - Yafo, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2029039
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Revenue | $1.2B |
| Operating income | -$4.9M |
| Net income | -$5.9M |
| Diluted EPS | -$0.72 |
| Operating cash flow | -$4.9M |
| Free cash flow | -$4.9M |
| Total assets | $5.0M |
| Total liabilities | $2.2M |
| Stockholders' equity | $2.8M |
| Cash and investments | $1.2M |
| Total debt | $118,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Sep 18, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 19, 2026 | Aug 19, 2026 |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Jun 30, 2026 |
All 100 Nasus Pharma Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.